{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T01:57:41Z","timestamp":1771639061519,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1200184"],"award-info":[{"award-number":["APP1200184"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s10620-024-08497-4","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T14:02:17Z","timestamp":1718805737000},"page":"3608-3613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An \u2018Adaptive Treatment Strategy\u2019 for Oral Vancomycin in Patients with the Orphan Disease Primary Sclerosing Cholangitis"],"prefix":"10.1007","volume":"69","author":[{"given":"Ayesha","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Tabibian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Buness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0206-2358","authenticated-orcid":false,"given":"Gerald J.","family":"Holtmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"8497_CR1","first-page":"126","volume":"19","author":"GC Smith","year":"2006","unstructured":"Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. Int J Prosthodont 2006; 19: 126\u2013128.","journal-title":"Int J Prosthodont"},{"key":"8497_CR2","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s10198-021-01427-5","volume":"23","author":"DT Michaeli","year":"2022","unstructured":"Michaeli DT, Yagmur HB, Achmadeev T, Michaeli T. Value drivers of development stage biopharma companies. Eur J Health Econ 2022; 23: 1287\u20131296.","journal-title":"Eur J Health Econ"},{"key":"8497_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s43441-021-00364-y","volume":"56","author":"DT Michaeli","year":"2022","unstructured":"Michaeli DT, Yagmur HB, Achmadeev T, Michaeli T. Valuation and returns of drug development companies: lessons for bioentrepreneurs and investors. Ther Innov Regul Sci 2022; 56: 313\u2013322.","journal-title":"Ther Innov Regul Sci"},{"key":"8497_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073242","volume":"381","author":"T Michaeli","year":"2023","unstructured":"Michaeli T, J\u00fcrges H, Michaeli DT. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis. BMJ 2023; 381: e073242.","journal-title":"BMJ"},{"key":"8497_CR5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s13063-022-06312-x","volume":"23","author":"C Snowdon","year":"2022","unstructured":"Snowdon C, Kernaghan S, Moretti L, et al. Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer. Trials 2022; 23: 372.","journal-title":"Trials"},{"key":"8497_CR6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/hep.32771","volume":"77","author":"CL Bowlus","year":"2023","unstructured":"Bowlus CL, Arriv\u00e9 L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology (Baltim MD) 2023; 77: 659\u2013702.","journal-title":"Hepatology (Baltim MD)"},{"key":"8497_CR7","first-page":"293","volume":"14","author":"JH Tabibian","year":"2018","unstructured":"Tabibian JH, Ali AH, Lindor KD. Primary sclerosing cholangitis, Part 1: epidemiology, etiopathogenesis, clinical features, and treatment. Gastroenterol Hepatol 2018; 14: 293\u2013304.","journal-title":"Gastroenterol Hepatol"},{"key":"8497_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/gutjnl-2019-318416","volume":"69","author":"T Liwinski","year":"2020","unstructured":"Liwinski T, Zenouzi R, John C, et al. Alterations of the bile microbiome in primary sclerosing cholangitis. Gut 2020; 69: 665\u2013672.","journal-title":"Gut"},{"key":"8497_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41575-019-0116-z","volume":"16","author":"I Dickson","year":"2019","unstructured":"Dickson I. Gut microbiota-mediated liver inflammation in PSC. Nat Rev Gastroenterol Hepatol 2019; 16: 140\u2013141.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"8497_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1055\/s-0039-1688501","volume":"39","author":"A Shah","year":"2019","unstructured":"Shah A, Crawford D, Burger D, et al. Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta-analysis. Semin Liver Dis 2019; 39: 432\u2013441.","journal-title":"Semin Liver Dis"},{"key":"8497_CR11","first-page":"961","volume":"9","author":"B Brandsaeter","year":"2003","unstructured":"Brandsaeter B, Broome U, Isoniemi H, et al. Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2003; 9: 961\u2013969.","journal-title":"Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc"},{"key":"8497_CR12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3109\/00365521.2015.1036359","volume":"50","author":"B Fosby","year":"2015","unstructured":"Fosby B, Melum E, Bj\u00f8ro K, et al. Liver transplantation in the Nordic countries\u2014an intention to treat and post-transplant analysis from The Nordic Liver Transplant Registry 1982\u20132013. Scand J Gastroenterol 2015; 50: 797\u2013808.","journal-title":"Scand J Gastroenterol"},{"key":"8497_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1055\/s-0041-1730950","volume":"41","author":"KK Leung","year":"2021","unstructured":"Leung KK, Deeb M, Fischer SE, Gulamhusein A. Recurrent primary sclerosing cholangitis: current understanding, management, and future directions. Semin Liver Dis 2021; 41: 409\u2013420.","journal-title":"Semin Liver Dis"},{"key":"8497_CR14","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1002\/hep.31911","volume":"74","author":"M Martinez","year":"2021","unstructured":"Martinez M, Perito ER, Valentino P, et al. Recurrence of primary sclerosing cholangitis after liver transplant in children: an international observational study. Hepatology (Baltim MD) 2021; 74: 2047\u20132057.","journal-title":"Hepatology (Baltim MD)"},{"key":"8497_CR15","first-page":"453","volume":"9","author":"C Ponsioen","year":"2013","unstructured":"Ponsioen C. Diagnosis, prognosis, and management of primary sclerosing cholangitis. Gastroenterol Hepatol 2013; 9: 453\u2013465.","journal-title":"Gastroenterol Hepatol"},{"key":"8497_CR16","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/apt.14540","volume":"47","author":"JL Damman","year":"2018","unstructured":"Damman JL, Rodriguez EA, Ali AH, et al. Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. Aliment Pharmacol Ther 2018; 47: 886\u2013895.","journal-title":"Aliment Pharmacol Ther"},{"key":"8497_CR17","doi-asserted-by":"publisher","first-page":"10646","DOI":"10.1038\/s41598-021-90175-w","volume":"11","author":"D Aune","year":"2021","unstructured":"Aune D, Sen A, Norat T, Riboli E, Folseraas T. Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of cohort studies. Sci Rep 2021; 11: 10646.","journal-title":"Sci Rep"},{"key":"8497_CR18","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.3748\/wjg.v23.i19.3418","volume":"23","author":"K Tajiri","year":"2017","unstructured":"Tajiri K, Shimizu Y. Recent advances in the management of pruritus in chronic liver diseases. World J Gastroenterol 2017; 23: 3418\u20133426.","journal-title":"World J Gastroenterol"},{"key":"8497_CR19","first-page":"1633","volume":"35","author":"JK Dyson","year":"2015","unstructured":"Dyson JK, Elsharkawy AM, Lamb CA, et al. Fatigue in primary sclerosing cholangitis is associated with sympathetic over-activity and increased cardiac output. Liver Int Off J Int Assoc Study Liver 2015; 35: 1633\u20131641.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"8497_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12955-021-01739-3","volume":"19","author":"E Marcus","year":"2021","unstructured":"Marcus E, Stone P, Krooupa A-M, Thorburn D, Vivat B. Quality of life in primary sclerosing cholangitis: a systematic review. Health Qual Life Outcomes 2021; 19: 100.","journal-title":"Health Qual Life Outcomes"},{"key":"8497_CR21","first-page":"580","volume":"27","author":"KL Cox","year":"1998","unstructured":"Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1998; 27: 580\u2013583.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"8497_CR22","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/00365521.2020.1787501","volume":"55","author":"AH Ali","year":"2020","unstructured":"Ali AH, Damman J, Shah SB, et al. Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis. Scand J Gastroenterol 2020; 55: 941\u2013950.","journal-title":"Scand J Gastroenterol"},{"key":"8497_CR23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s12664-022-01286-9","volume":"41","author":"A Shah","year":"2022","unstructured":"Shah A, Pakneeshan S, Jones MP, et al. How frequent are vancomycin-resistant enterococci in patients with primary sclerosing cholangitis and ulcerative colitis treated with oral vancomycin? Indian J Gastroenterol 2022; 41: 519\u2013524.","journal-title":"Indian J Gastroenterol"},{"key":"8497_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","volume":"25","author":"S Rahimpour","year":"2016","unstructured":"Rahimpour S, Nasiri-Toosi M, Khalili H, Ebrahimi-Daryani N, Nouri-Taromlou MK, Azizi Z. A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study. J Gastrointest Liver Dis 2016; 25: 457\u2013464.","journal-title":"J Gastrointest Liver Dis"},{"key":"8497_CR25","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/apt.12232","volume":"37","author":"JH Tabibian","year":"2013","unstructured":"Tabibian JH, Weeding E, Jorgensen RA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis\u2014a pilot study. Aliment Pharmacol Ther 2013; 37: 604\u2013412.","journal-title":"Aliment Pharmacol Ther"},{"key":"8497_CR26","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/apt.17936","volume":"59","author":"A Ricciuto","year":"2024","unstructured":"Ricciuto A, Liu K, El-Matary W, et al. Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): a matched analysis from the Paediatric PSC Consortium. Aliment Pharmacol Ther 2024; 59: 1236\u20131247.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08497-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-024-08497-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08497-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T18:05:34Z","timestamp":1729274734000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-024-08497-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["8497"],"URL":"https:\/\/doi.org\/10.1007\/s10620-024-08497-4","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]},"assertion":[{"value":"11 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"<b>GH<\/b> report to be on the advisory boards Australian Biotherapeutics, Glutagen, Bayer and received research support from Bayer, Abbott, Pfizer, Janssen, Takeda, Allergan. He serves on the Board of West Moreton Hospital and Health Service, Queensland, UQ Healthcare, Brisbane and the Gastro-Liga, Germany. He has a patent for the Brisbane aseptic biopsy device. Editor of the Gastro-Liga Newsletter.<b>JHT<\/b> is a Consultant for AlphaSights, Atheneum, ClearView Healthcare Partners, DeciBio, Gerson Lerman Group, Guidepoint Global Advisors, Horizon Therapeutics, Olympus Corporation, iota Biosciences, Ipsen, KeyQuest Health, Pure Healthcare Strategy, Techspert, Teladoc Health.<b>Other co-authors<\/b> None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}